Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The authors concluded that chronic telogen effluvium in middle-aged women presents distinct clinical and histological features that differ from androgenetic alopecia and acute telogen effluvium.

This review discusses the mechanisms, causes, and treatment options for telogen effluvium, noting acute cases often resolve by addressing causative factors, while chronic forms remain challenging to treat; recent causes include post-hair transplantation, vitamin D deficiency, and COVID-19.

This continuing medical education article outlines the comprehensive approach needed to diagnose alopecia, emphasizing the importance of a thorough history, scalp and hair examination, and, if necessary, laboratory analysis and biopsy for effective treatment planning.

In this study, trichoscopy was found to be an effective noninvasive tool for diagnosing female pattern hair loss at early stages, potentially eliminating the need for scalp biopsies.

This study observed that female patients with chronic telogen effluvium had significantly lower levels of total thiol, thiol-disulphide, and disulphide compared to healthy controls, indicating a disruption in oxidative stress balance.

This review of Leon Sperling's Atlas of Hair Pathology discusses the visual and diagnostic value of its comprehensive coverage on hair and scalp diseases but reports no new clinical findings.

This article discusses the historic use of oral minoxidil for severe hypertension and the subsequent development of a topical formulation for treating pattern hair loss, but reports no new results.

This case report describes a 16-year-old girl initially diagnosed with chronic telogen effluvium, later reassessed with Ludwig Stage 1 androgenetic alopecia, for which she began spironolactone treatment.

This review determined that chronic telogen effluvium lacks a consistent definition and may often be misdiagnosed, as it could represent either early female pattern hair loss or secondary telogen effluvium without identified causes.

This review examines chronic telogen effluvium, highlighting its distinctive features and the need for reassurance about its non-progressive nature, but reports no new clinical results.

This article reviews various causes and investigative techniques for different forms of alopecia and reports no new findings.

The document concludes that while some hair and scalp disorders can be treated, hair loss from destroyed follicles is permanent, and damaged hair can only regrow naturally.

This review highlights evidence supporting the potential of blue light therapy as a non-invasive treatment for managing skin and hair conditions by modulating interactions between the skin microbiome and its host.

In this study, four women with chronic telogen effluvium experienced fluctuating hair shedding without visible reduction in hair density or follicular miniaturization over at least 7 years.

This study suggests that chronic telogen effluvium may be due to a reduction in the variance of anagen duration, resulting in recurrent hair shedding with minimal long-term hair volume loss.

This article describes a rare case of chronic telogen effluvium in a man, suggesting that the condition might be more noticeable in individuals with long hair; it does not report new research findings.

This study compared serum zinc, vitamin B12, folic acid levels, iron metabolism, and thyroid function between chronic telogen effluvium patients and healthy controls, but it reports no specific clinical results.

This study found a strong association between chronic telogen effluvium and low levels of hemoglobin, serum ferritin, and thyroid hormones in premenopausal Indian women, with stress also playing a significant role.

This review discusses the phases of the human hair cycle and highlights the importance of identifying factors that disturb it, but reports no new clinical findings.

In this study, women with chronic telogen effluvium experienced reduced hair shedding after being treated with once daily oral minoxidil for 12 months, but facial hypertrichosis was a reported side effect, suggesting the need for further placebo-controlled research.

This case study reports the first documentation of the intermittent nature of chronic telogen effluvium and suggests a link between emotional stress and hair shedding severity.

This article is a letter to the editor discussing hair graying and loss potentially induced by imatinib mesylate, but it does not provide new research results.

In this study conducted in the Makkah region, researchers observed that hair loss, mostly telogen effluvium, is a prevalent post-COVID-19 symptom, particularly among women and those with multiple health issues.

This study found that women with chronic telogen effluvium had significantly lower serum ferritin levels and higher TIBC levels compared to normal females, suggesting a potential role for iron stores in the condition's pathogenesis.

Oral minoxidil effectively reduces hair shedding in women with chronic telogen effluvium.

Oral minoxidil significantly reduces hair shedding in women with chronic telogen effluvium.

The researchers reported that adult menstruating females with chronic telogen effluvium had significantly lower serum zinc levels compared to healthy controls, suggesting an association between decreased zinc levels and CTE.

This case report describes a 27-year-old woman with a family history of hair thinning and a 6-year history of alopecia on the scalp.

Low-dose oral minoxidil is a promising, safe treatment for various hair diseases, improving hair thickness and density, but more research is needed on long-term side effects and treatment duration.

This study observed that chronic kidney disease patients undergoing hemodialysis frequently experience dermatologic manifestations, with xerosis and white nail being the most common skin and nail changes noted in 74% and 56% of patients, respectively.